7790 results for "canc*"

in 46.31 milliseconds.

• Normal sample for patient SA287

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA287

  Dataset EGAD00001009228

• Normal sample for patient SA394

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA394

  Dataset EGAD00001009229

• Normal sample for patient SA395

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA395

  Dataset EGAD00001009230

• Normal sample for patient SA398

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA398

  Dataset EGAD00001009231

• Normal sample for patient SA402

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA402

  Dataset EGAD00001009232

• Normal sample for patient SA404

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA404

  Dataset EGAD00001009233

• Normal sample for patient SA530

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA530

  Dataset EGAD00001009234

• Normal sample for patient SA535

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA535

  Dataset EGAD00001009235

• Normal sample for patient SA585

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA585

  Dataset EGAD00001009236

• Normal sample for patient SA586

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA586

  Dataset EGAD00001009237

• Normal sample for patient SA588

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA588

  Dataset EGAD00001009238

• Normal sample for patient SA589

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA589

  Dataset EGAD00001009239

• Normal sample for patient SA590

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA590

  Dataset EGAD00001009240

• Normal sample for patient SA591

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA591

  Dataset EGAD00001009241

• Normal sample for patient SA592

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA592

  Dataset EGAD00001009242

• Normal sample for patient SA593

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA593

  Dataset EGAD00001009243

• Tumour sample for patient SA599

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA599

  Dataset EGAD00001009203

• Tumour sample for patient SA600

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA600

  Dataset EGAD00001009204

• Tumour sample for patient SA601

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA601

  Dataset EGAD00001009205

• Tumour sample for patient SA654

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA654

  Dataset EGAD00001009206

• Tumour sample for patient SA655

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA655

  Dataset EGAD00001009207

• Tumour sample for patient SA665

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA665

  Dataset EGAD00001009208

• Tumour sample for patient SA666

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA666

  Dataset EGAD00001009209

• Tumour sample for patient SA598

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA598

  Dataset EGAD00001009202

• Tumour sample for patient SA596

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA596

  Dataset EGAD00001009201

• Tumour sample for patient SA595

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA595

  Dataset EGAD00001009200

• Tumour sample for patient SA593

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA593

  Dataset EGAD00001009199

• Tumour sample for patient SA592

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA592

  Dataset EGAD00001009198

• Tumour sample for patient SA591

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA591

  Dataset EGAD00001009197

• Tumour sample for patient SA590

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA590

  Dataset EGAD00001009196

• Tumour sample for patient SA589

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA589

  Dataset EGAD00001009195

• Tumour sample for patient SA588

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA588

  Dataset EGAD00001009194

• Normal sample for patient SA595

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA595

  Dataset EGAD00001009244

• Normal sample for patient SA598

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA598

  Dataset EGAD00001009246

• Normal sample for patient SA599

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA599

  Dataset EGAD00001009247

• Normal sample for patient SA600

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA600

  Dataset EGAD00001009248

• Normal sample for patient SA601

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA601

  Dataset EGAD00001009249

• Normal sample for patient SA654

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA654

  Dataset EGAD00001009250

• Normal sample for patient SA655

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA655

  Dataset EGAD00001009251

• Normal sample for patient SA665

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA665

  Dataset EGAD00001009252

• Normal sample for patient SA667

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA667

  Dataset EGAD00001009253

• Normal sample for patient SA668

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA668

  Dataset EGAD00001009254

• Normal sample for patient SA669

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA669

  Dataset EGAD00001009255

• Normal sample for patient SA671

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA671

  Dataset EGAD00001009256

• Normal sample for patient SA672

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA672

  Dataset EGAD00001009257

• Tumour sample for patient SA1035

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1035

  Dataset EGAD00001009258

• Tumour sample for patient SA994

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA994

  Dataset EGAD00001009259

• Tumour sample for patient SA604

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA604

  Dataset EGAD00001009260

• Tumour sample for patient SA605

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA605

  Dataset EGAD00001009261

• Tumour sample for patient SA609

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA609

  Dataset EGAD00001009262

• Normal sample for patient SA596

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA596

  Dataset EGAD00001009245

• Widespread hypertranscription in aggressive human cancers

  Data used to validate RNAmp tool.

  Dataset EGAD00001009285

• Clinical cancer panel sequencing (UCSF500) analysis of TERT promoter duplication in GBM.

  Dataset contains paired-end clinical cancer panel sequencing (UCSF500) data from 2 samples of an initial tumor and one sample of a recurrence from one GBM patient and one sample from a second GBM patient.

  Dataset EGAD00001009286

• Tumour sample for patient SA218

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA218

  Dataset EGAD00001009177

• Tumour sample for patient SA219

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA219

  Dataset EGAD00001009178

• Tumour sample for patient SA272

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA272

  Dataset EGAD00001009179

• Tumour sample for patient SA274

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA274

  Dataset EGAD00001009180

• Tumour sample for patient SA275

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA275

  Dataset EGAD00001009181

• Tumour sample for patient SA276

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA276

  Dataset EGAD00001009182

• Tumour sample for patient SA279

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA279

  Dataset EGAD00001009183

• Tumour sample for patient SA283

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA283

  Dataset EGAD00001009184

• Tumour sample for patient SA287

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA287

  Dataset EGAD00001009185

• Tumour sample for patient SA394

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA394

  Dataset EGAD00001009186

• Tumour sample for patient SA395

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA395

  Dataset EGAD00001009187

• Tumour sample for patient SA398

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA398

  Dataset EGAD00001009188

• Tumour sample for patient SA402

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA402

  Dataset EGAD00001009189

• Tumour sample for patient SA404

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA404

  Dataset EGAD00001009190

• Tumour sample for patient SA530

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA530

  Dataset EGAD00001009191

• Tumour sample for patient SA585

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA585

  Dataset EGAD00001009192

• 10x Genomics Single Cell Gene Expression for SA1035X4XB02879

  10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA1035 passage 4

  Dataset EGAD00001009147

• 10x Genomics Single Cell Gene Expression for SA1035X8XB03425

  10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA1035 passage 8

  Dataset EGAD00001009148

• 10x Genomics Single Cell Gene Expression for SA535X6XB03101

  10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA535 passage 6

  Dataset EGAD00001009149

• 10x Genomics Single Cell Gene Expression for SA1035X6XB03211

  10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA1035 passage 6

  Dataset EGAD00001009150

• 10x Genomics Single Cell Gene Expression for SA1035X7XB03502

  10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA1035 passage 7

  Dataset EGAD00001009151

• 10x Genomics Single Cell Gene Expression for SA535X4XB02498

  10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA535 passage 4

  Dataset EGAD00001009152

• 10x Genomics Single Cell Gene Expression for SA1035X5XB03021

  10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA1035 passage 5

  Dataset EGAD00001009153

• 10x Genomics Single Cell Gene Expression for SA1035X6XB03216

  10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA1035 passage 6

  Dataset EGAD00001009154

• 10x Genomics Single Cell Gene Expression for SA535X5XB02891

  10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA535 passage 5

  Dataset EGAD00001009155

• 10x Genomics Single Cell Gene Expression for SA535X5XB02895

  10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA535 passage 5

  Dataset EGAD00001009156

• 10x Genomics Single Cell Gene Expression for SA535X9XB03617

  10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA535 passage 9

  Dataset EGAD00001009157

• 10x Genomics Single Cell Gene Expression for SA604X9XB02425

  10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA604 passage 9

  Dataset EGAD00001009159

• 10x Genomics Single Cell Gene Expression for SA610X3XB03802

  10x Genomics Single Cell Gene Expression for Triple negative breast cancer patient-derived xenograft SA610 passage 3

  Dataset EGAD00001009160

• MESA colorectal cancer cfDNA EM-seq dataset

  This dataset contains the methylation sequencing data of 60 nonCancer and 70 colorectal cancer cfDNA samples. The methylation library is constructed by using NEBNext Enzymatic-seq Kit.

  Dataset EGAD00001009165

• RNAseq analysis on metastatic Colorectal Cancer xenografts samples

  Bank of metastatic colorectal cancer (mCRC) of Patient Derived Xenografts (PDXs)

  Dataset EGAD00001009171

• Colorectal cancer samples WES

  The whole exome was sequenced in two cancer-affected members (II:1 and III:1) of the family. The family subject of this study showed an autosomal dominant mode of CRC inheritance, fulfilling the Amsterdam I clinical criteria with three CRCs in two consecutive generations. The exome capture was performed using SureSelectXT Human All Exon V3 (51Mb, Agilent Technologies), and the library was sequenced on an Illumina HiSeq 2000 platform with paired-end reads of 101bp and a 50x average coverage depth.

  Dataset EGAD00001009170

• Bulk RNA-seq of stromal cells from multiple cancer types

  We sorted CD45-CD44+CD90+ stromal cells from multiple tumor types and performed bulk RNA-sequencing.

  Dataset EGAD00001009176

• Tumour sample for patient SA586

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA586

  Dataset EGAD00001009193

• Type 1 interferon perturbates clonal competition by reshaping human blood development

  We studied hematopoietic stem cells, progenitors and immune cells from patients with myeloproliferative neoplasms (MPN) at baseline and following interferon-⍺ (IFN⍺) treatment, the only therapy to deplete mutated stem cells. We deployed single-cell multi-omics methods that distinguish the IFN⍺ effects on mutated stem cells from the admixed wildtype HSCs, with respect to their differentiation, transcriptomes, immunophenotypes, and chromatin accessibility.

  Study EGAS50000002009

• FGFR2b Prevalence in Biliary Tract Cancers

  Patients with intrahepatic cholangiocarcinoma (iCCA) often have limited effective treatment options after first-line therapy. Actionable driver mutations are present in only a small subset of patients with iCCA; therefore, therapeutic strategies such as antibody–drug conjugates (ADCs) that do not exclusively rely on presence of specific oncogenic mutations may be particularly attractive. However, there is a critical lack of knowledge regarding prevalent and actionable cell-surface targets in iCCA. We applied a novel isoform-resolved proteogenomic discovery framework for profiling cell surface targets and identified FGFR2b, a splicing isoform of FGFR2, as a therapeutic target in iCCA that is highly-expressed, tumor-enriched, localized to the membrane, and associated with prognosis. FGFR2b is the dominant isoform in iCCA, and it was present in all patients with FGFR2 fusions. These findings provide a strong rationale for further research and therapeutic development of FGFR2b-targeted biologics, including therapeutic antibodies and ADCs, in iCCA.

  Study EGAS50000002012

• Cancers of Unknow Primary

  genetic data of 14 rigorously selected CUP samples

  Dataset EGAD00001009426

• Single Cell Genome Sequence for DLP+ library A110660A

  Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA610 passage 3 on DLP+ library A110660A

  Dataset EGAD00001009430

• Single Cell Genome Sequence for DLP+ library A96212B

  Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA604 passage 7 on DLP+ library A96212B

  Dataset EGAD00001009476

• Single Cell Genome Sequence for DLP+ library A96213A

  Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA501 passage 6, cell line SA1090 on DLP+ library A96213A

  Dataset EGAD00001009477

• Single Cell Genome Sequence for DLP+ library A98181A

  Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA919 passage 7, patient-derived xenograft SA1050A passage 1 on DLP+ library A98181A

  Dataset EGAD00001009479

• Single Cell Genome Sequence for DLP+ library A98240A

  Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA530 passage 3 on DLP+ library A98240A

  Dataset EGAD00001009480

• Tracking the evolution of esophageal squamous cell carcinoma under dynamic immune selection by multi-omics sequencing

  Intratumoral heterogeneity (ITH) has been linked to decreased efficacy of clinical treatments. However, although genomic ITH has been characterized in genetic, transcriptomic and epigenetic alterations are hallmarks of esophageal squamous cell carcinoma (ESCC), the extent to which these are heterogeneous in ESCC has not been explored in a unified framework. Further, the extent to which tumor-infiltrated T lymphocytes (TILs) are directed against cancer cells, but how the immune infiltration acts as a selective force to shape the clonal evolution of ESCC is unclear. In this study, we perform multi-omic sequencing on 186 samples from 36 primary ESCC patients. Through multi-omics analyses, it is discovered that genomic, epigenomic, and transcriptomic ITH are underpinned by ongoing chromosomal instability. Based on the RNA-seq data, we observe diverse levels of immune infiltrate across different tumor sites from the same tumor. We reveal genetic mechanisms of neoantigen evasion under distinct selection pressure from the diverse immune microenvironment. Overall, our work offers an avenue of dissecting the complex contribution of the multi-omics level to the ITH in ESCC and thereby enhances the development of clinical therapy.

  Dataset EGAD00001009482

• Single Cell Genome Sequence for DLP+ library A95621B

  Single Cell Genome Sequence for triple negative breast cancer patient-derived xenograft SA501 passage 2 on DLP+ library A95621B

  Dataset EGAD00001009487

• CASCADE low-pass whole genome sequencing data

  Low-pass whole genome sequencing data (median coverage: 0.37X, range: 0.07X-5.8X) from diagnostic formalin-fixed paraffin-embedded tissue and fresh frozen postmortem tissues from ten organs and postmortem blood from patients who participated in the CASCADE rapid autopsy program and died of metastatic castration resistant prostate cancer. For samples CA27_11, CA34_10, CA35_5, CA35_6, CA36_3, CA36_11, CA63_13, CA63_34, CA76_4, CA76_11, CA79_4, CA83_14 and CA83_26, we subsampled (using `samtools view -s 0.01` after mapping) from respective high coverage data from "CASCADE tumour high-coverage whole genome sequencing data" dataset.

  Dataset EGAD00001009494

• CASCADE tumour transcriptome data

  RNA-Seq data from 20 fresh-frozen postmortem samples from three patients who participated in the CASCADE rapid autopsy program and died of metastatic castration resistant prostate cancer.

  Dataset EGAD00001009492

• CASCADE germline whole genome sequencing data

  High-coverage whole genome sequencing data (median coverage: 23.5X, range: 14.14X-32.62X)) from white blood cells of the patients from isolated buffy coat of the blood drawn postmortem from patients who participated in the CASCADE rapid autopsy program and died of metastatic castration resistant prostate cancer.

  Dataset EGAD00001009493